DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
First Investment: 2019
People who beat cancer, or have neurodegenerative conditions that are very slow to progress, may harbor naturally occurring protective antibodies that make them more resilient against these devastating diseases. Alchemab sequences the B cells of these individuals, uses AI to identify groups of related antibodies across the resilient population, finds the binding targets of these antibodies, and uses that information to design treatments that could help other patients fight solid tumors, infections, or Alzheimer’s.
Explore Companies
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules
Visolis
Using synthetic biology to manufacture carbon-negative materials